- Home
- DOW vs NTRA Comparison
DOW vs NTRA Comparison
Compare DOW & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOW
- NTRA
- Stock Information
- Founded
- DOW 1897
- NTRA 2003
- Country
- DOW United States
- NTRA United States
- Employees
- DOW N/A
- NTRA N/A
- Industry
- DOW Major Chemicals
- NTRA Medical Specialities
- Sector
- DOW Industrials
- NTRA Health Care
- Exchange
- DOW Nasdaq
- NTRA Nasdaq
- Market Cap
- DOW 21.6B
- NTRA 21.5B
- IPO Year
- DOW N/A
- NTRA 2015
- Fundamental
- Price
- DOW $27.77
- NTRA $171.86
- Analyst Decision
- DOW Hold
- NTRA Strong Buy
- Analyst Count
- DOW 15
- NTRA 16
- Target Price
- DOW $38.27
- NTRA $185.56
- AVG Volume (30 Days)
- DOW 9.6M
- NTRA 1.2M
- Earning Date
- DOW 07-24-2025
- NTRA 08-07-2025
- Dividend Yield
- DOW 10.09%
- NTRA N/A
- EPS Growth
- DOW N/A
- NTRA N/A
- EPS
- DOW 0.40
- NTRA N/A
- Revenue
- DOW $42,630,000,000.00
- NTRA $1,831,000,000.00
- Revenue This Year
- DOW N/A
- NTRA $19.92
- Revenue Next Year
- DOW $2.78
- NTRA $16.02
- P/E Ratio
- DOW $69.70
- NTRA N/A
- Revenue Growth
- DOW N/A
- NTRA 51.50
- 52 Week Low
- DOW $25.06
- NTRA $92.14
- 52 Week High
- DOW $55.97
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- DOW 40.46
- NTRA 66.42
- Support Level
- DOW $29.79
- NTRA $161.39
- Resistance Level
- DOW $30.61
- NTRA $169.17
- Average True Range (ATR)
- DOW 0.94
- NTRA 4.86
- MACD
- DOW -0.02
- NTRA 0.57
- Stochastic Oscillator
- DOW 27.19
- NTRA 90.95
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.